4D Molecular Therapeutics, Inc. (FDMT) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "FDMT"
      ],
      "issuer_cik": "0001650648",
      "owner_cik": "0001920738",
      "accession_number": "0001193125-26-426810",
      "form_type": "4",
      "filing_date": "2026-10-20",
      "period_of_report": "2026-10-16",
      "issuer_name": "4D Molecular Therapeutics, Inc.",
      "issuer_trading_symbol": "FDMT",
      "owner_name": "Bizily Scott",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "Chief Legal Officer",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-16",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 1635,
      "transaction_price_per_share": 12.84,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 8617,
      "transaction_value": 20993.4,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."
        }
      ]
    },
    {
      "tickers": [
        "FDMT"
      ],
      "issuer_cik": "0001650648",
      "owner_cik": "0001834021",
      "accession_number": "0001193125-26-417068",
      "form_type": "4",
      "filing_date": "2026-10-07",
      "period_of_report": "2026-10-05",
      "issuer_name": "4D Molecular Therapeutics, Inc.",
      "issuer_trading_symbol": "FDMT",
      "owner_name": "Kirn David",
      "is_director": true,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "See Remarks",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-05",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 58061,
      "transaction_price_per_share": 12.9215,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 709425,
      "transaction_value": 750235.2115,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."
        },
        {
          "id": "F2",
          "description": "The transaction was executed in multiple trades in prices ranging from $12.61 to $13.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."
        }
      ],
      "remarks": "President and Chief Executive Officer"
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.